Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Peripheral T-cell lymphoma

Peripheral T-cell lymphoma

Part of Non-Hodgkin's Lymphoma

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials for Peripheral T-cell lymphoma

50 trials tracked for Peripheral T-cell lymphoma: 1 in phase 3 or 4 and 1 with published results. The most-cited published study has 35 citations.

50Trials tracked
1Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 4 1 Phase 2 40 Phase 1 6 Other / NA 3
  1. Phase 4 Treatment of Peripheral T-cell Lymphoma Completed · 35 cited
  2. Phase 2 A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma Completed
  3. Phase 2 A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL) Completed
  4. Phase 2 A Pilot Study to Determine the Safety of the Combination of Ontak in Combination With CHOP in Peripheral T-Cell Lymphoma Completed
  5. Phase 2 Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer Completed
  6. Phase 2 Extension Study in Subjects Who Relapsed After Complete Response on Study KW-0761-001 Completed
Show 44 more trials
  1. Phase 2 Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Completed
  2. Phase 2 Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms Completed
  3. Phase 2 A Japanese Phase 1/2 Study to Assess the Efficacy, Safety and Pharmacokinetics of Romidepsin in Patients With Peripheral T-cell Lymphoma (PTCL) Completed
  4. Phase 2 Study of Pralatrexate With Vitamin B12 and Folic Acid in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Completed
  5. Phase 2 Phase II Study to Assess AFM13 in Patients With R/R CD30-positive T-cell Lymphoma or Transformed Mycosis Fungoides Completed
  6. Phase 2 Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell Lymphomas Completed
  7. Phase 2 Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab Completed
  8. Phase 2 Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma Completed
  9. Phase 2 A Study of ONTAK and CHOP in Newly Diagnosed, Peripheral T-Cell Lymphoma Completed
  10. Phase 2 Depsipeptide to Treat Patients With Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma Completed
  11. Phase 2 Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL Completed
  12. Phase 2 Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer Completed
  13. Phase 2 Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma Completed
  14. Phase 2 Phase II Study of Gemcitabine+Romidepsin in the Relapsed/Refractory Peripheral T-cell Lymphoma Patients Completed
  15. Phase 2 Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies Completed
  16. Phase 2 Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies Completed
  17. Phase 2 Study of E7777 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma and Cutaneous T-cell Lymphoma Completed
  18. Phase 2 Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies Completed
  19. Phase 2 Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma Completed
  20. Phase 2 Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma Completed
  21. Phase 2 Nivolumab and the Antagonistic CSF-1R Monoclonal Antibody Cabiralizumab (BMS-986227) in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma Completed
  22. Phase 2 Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma Completed
  23. Phase 2 A Phase 2 Study of SP-02L in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) Completed
  24. Phase 2 Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer Completed
  25. Phase 2 ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas Completed
  26. Phase 2 Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma Completed
  27. Phase 2 Safety Study to Evaluate Monoclonal Antibody KW-0761 in Subjects With Peripheral T-cell Lymphoma Completed
  28. Phase 2 Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin's Lymphoma Completed
  29. Phase 2 Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies Completed
  30. Phase 2 A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression Completed
  31. Phase 2 Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies Completed
  32. Phase 2 Safety and Efficacy of Pentostatin and Low Dose TBI With Allogenic Peripheral Blood Stem Cell Transplant Completed
  33. Phase 2 Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies Completed
  34. Phase 2 A Study of Duvelisib in Participants With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) Completed
  35. Phase 2 Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma Completed
  36. Phase 1 Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas Completed
  37. Phase 1 E7777 for the Treatment of Patients With Peripheral T-Cell Lymphoma Completed
  38. Phase 1 Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies Completed
  39. Phase 1 Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma Completed
  40. Phase 1 T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas Completed
  41. Phase 1 A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma Completed
  42. N/A Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer Completed
  43. N/A High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors Completed
  44. N/A Special Drug Use Surveillance for Brentuximab Vedotin Intravenous Infusion "Relapsed or Refractory CD30-positive Peripheral T Cell Lymphoma or Pediatric Hodgkin Lymphoma" Completed

Showing the 50 most-cited and recently-updated of 50 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Peripheral T-cell lymphoma: what the trials found

Established evidence for the use of Nivolumab includes a complete response rate of 11 (p=0.1) in a study of 18 patients 5, and an overall response rate (ORR) at four months as well as a complete response rate (CRR) of 2 in a small cohort of 4 patients 13.

Brentuximab vedotin has been evaluated in multiple trials, including cohorts of 82 3 and 131 7 patients.

KW-0761 was evaluated in both a larger cohort of 42 patients 15 and a single-patient study 16.

Recent results — preliminary, needs further review

  • ALRN-6924 is currently being investigated in a phase 2 trial involving 142 participants 1.

For the clinician treating this condition

  • Nivolumab has demonstrated measurable response rates (CRR and ORR) in small patient populations.
  • Brentuximab vedotin and KW-761 have established clinical trial footprints for this condition.
  • Newer agents such as ALRN-6924 are currently undergoing phase 2 investigation.

AI synthesis of 7 cited trials, updated Jun 26, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Mitoxantrone liposome plus CMOP shows high response rates in untreated peripheral T-cell lymphoma patients
Oncology Phase I
Mitoxantrone liposome plus CMOP shows high response rates in untreated peripheral T-cell lymphoma patients New Drug Combo Helps Most Patients With Hard-to-Treat Lymphoma
This phase 1b multicenter clinical trial evaluated mitoxantrone hydrochloride liposome combined with cyclophosphamide, vincristine, and pred…
A new drug combo wrapped in fat bubbles helped 89% of patients with hard-to-treat lymphoma shrink tumors without causing deaths.
Apr 12, 2026

Research across Non-Hodgkin's Lymphoma

Related studies from across the Non-Hodgkin's Lymphoma family.

miR-155 overexpression is frequently associated with treatment resistance across 8 cancer types
Drug Pipeline Meta-analysis
miR-155 overexpression is frequently associated with treatment resistance across 8 cancer types miR-155 Expression Linked to Treatment Resistance in Various Cancers
This systematic review of 19 studies across 8 cancer types indicates that miR-155 overexpression is associated with treatment resistance in …
Research suggests that high levels of a specific molecule, miR-155, may be linked to how well certain cancers respond to treatment.
Frontiers Oct 21, 2026
BTK inhibitors do not significantly increase second primary malignancy risk in B-cell lymphoma patients
Hematology Meta-analysis
BTK inhibitors do not significantly increase second primary malignancy risk in B-cell lymphoma patients BTK inhibitors do not appear to cause second primary cancers
This meta-analysis of 9337 patients found that BTK inhibitors do not significantly increase the risk of second primary malignancies compared…
New data suggests that a common class of drugs used to treat certain blood cancers does not increase the risk of developing new cancers.
Oct 1, 2026
Brexucabtagene autoleucel achieves 88% overall response rate in relapsed or refractory mantle cell lymphoma
Oncology Meta-analysis
Brexucabtagene autoleucel achieves 88% overall response rate in relapsed or refractory mantle cell lymphoma Trial Shows Brexucabtagene Autoleucel Provides Durable Benefit for Blood Cancers
This meta-analysis of 31 cohorts evaluates brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma and B-cell acute lympho…
Brexucabtagene autoleucel shows high response rates and durable benefits for adults with specific types of relapsed or refractory blood canc…
Oct 1, 2026
Allo-HSCT after CAR-T yields sustained remission in DLBCL patient with secondary MDS
Diabetes & Endocrinology Sys. Review
Allo-HSCT after CAR-T yields sustained remission in DLBCL patient with secondary MDS CAR-T and transplant may lead to secondary leukemia
This case report and literature review describes a single patient with primary splenic DLBCL who developed secondary myelodysplastic syndrom…
A patient developed a secondary blood cancer after CAR-T therapy and transplant, but a later transplant brought remission.
Frontiers Aug 27, 2026
Multifaceted preventive nursing program reduces fall incidence from 19.8% to 7.1% in elderly NHL patients
Oncology RCT
Multifaceted preventive nursing program reduces fall incidence from 19.8% to 7.1% in elderly NHL patients Nursing Program Reduces Fall Risk for Lymphoma Patients
This randomized controlled trial of 210 older adults with non-Hodgkin's lymphoma found that a multifaceted preventive nursing program signif…
A specialized nursing program significantly reduced falls and improved mobility for older adults undergoing chemotherapy for lymphoma.
Jul 20, 2026
IL-10 rs1800890 variants linked to modestly increased non-Hodgkin lymphoma risk in meta-analysis
Oncology Meta-analysis
IL-10 rs1800890 variants linked to modestly increased non-Hodgkin lymphoma risk in meta-analysis Gene Variants Linked to Higher Non-Hodgkin Lymphoma Risk
This meta-analysis of 53,864 cases and 60,448 controls found that certain IL-10 polymorphisms (rs1800890 and rs1800896) are associated with …
Certain IL-10 gene variants may slightly raise the risk of non-Hodgkin lymphoma, a large analysis finds.
Jul 4, 2026
CAR-T cell therapy improves progression-free survival (HR 0.55) and overall survival (HR 0.68) in R/R DLBCL
Oncology Meta-analysis
CAR-T cell therapy improves progression-free survival (HR 0.55) and overall survival (HR 0.68) in R/R DLBCL CAR-T cell therapy shows improved survival for certain blood cancers
This meta-analysis of 2150 adult patients with relapsed or refractory diffuse large B-cell lymphoma found that CAR-T cell therapy significan…
New analysis shows CAR-T cell therapy significantly improves survival and response rates for patients with relapsed or refractory DLBCL.
Jul 3, 2026
Impact of Body Mass Index Categories on Outcomes in Patients with DLBCL
Nutrition & Obesity Medicine Meta-analysis
Impact of Body Mass Index Categories on Outcomes in Patients with DLBCL Overweight status linked to better survival in certain lymphoma
A meta-analysis reveals that overweight status correlates with improved survival in DLBCL, while underweight status is linked to poorer clin…
Patients with diffuse large B-cell lymphoma who are overweight may have better survival outcomes than those who are underweight.
Frontiers Jun 24, 2026
Pola-R-CHP reduces progression risk 35% in double-expressor DLBCL, but OS unchanged
Allergy & Immunology Meta-analysis
Pola-R-CHP reduces progression risk 35% in double-expressor DLBCL, but OS unchanged New Treatment Options Show Promise for Specific Lymphoma Patients
This network meta-analysis of 1,016 treatment-naïve patients with MYC/BCL2 double-expressor DLBCL found that Pola-R-CHP significantly reduce…
A new drug combination may reduce the risk of disease progression in patients with a specific type of lymphoma.
Frontiers Jun 23, 2026
Rituximab plus lenalidomide provides comparable progression-free survival to rituximab-based immunochemotherapy in advanced follicular lymphoma
Oncology RCT
Rituximab plus lenalidomide provides comparable progression-free survival to rituximab-based immunochemotherapy in advanced follicular lymphoma Trial shows lenalidomide and rituximab for advanced follicular lymphoma
This Phase 3 randomized controlled trial of 1030 patients with previously untreated advanced follicular lymphoma found that the combination …
A large trial shows that a combination of two drugs can serve as an effective alternative to chemotherapy for patients with advanced follicu…
Blood Jun 20, 2026
Tafasitamab plus lenalidomide and R-CHOP improves progression-free survival in high-risk DLBCL
Oncology RCT
Tafasitamab plus lenalidomide and R-CHOP improves progression-free survival in high-risk DLBCL Trial shows new treatment improves progression-free survival for lymphoma
This Phase 3 randomized, double-blind, placebo-controlled trial evaluated tafasitamab plus lenalidomide and R-CHOP in patients with high-ris…
A new drug combination showed improved progression-free survival for patients with high-risk large B-cell lymphoma in a Phase 3 clinical tri…
Jun 20, 2026
Solid organ transplant recipients face higher cancer-related mortality with SMR 2.21 across multiple organs
Allergy & Immunology Meta-analysis
Solid organ transplant recipients face higher cancer-related mortality with SMR 2.21 across multiple organs Organ transplant recipients face higher risk of certain cancers
This meta-analysis of multi-centre cohort and registry-based studies indicates that solid organ transplant recipients experience significant…
People who receive heart or lung transplants face a significantly higher risk of dying from specific types of cancer.
Frontiers Jun 20, 2026